Anebulo PharmaceuticalsANEB
13F holders, Q2 2024 (June 30)13holders −2
1new positions
3sold out
$2.73avg. 13F price*
At the end of Q2 2024, 13 institutions reported holding Anebulo Pharmaceuticals Inc. (ANEB) in their 13F filings, down 2 from Q1 2024. 1 opened new positions and 3 sold out. The largest holders were 22NW, LP ($14.6M), LVW Advisors, LLC ($1.8M) and Nantahala Capital Management, LLC ($1.4M).
- Company
- Anebulo Pharmaceuticals Inc.
- CUSIP
- 034569103
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $177 |
| Exits | 3 | $73K |
All 13F filers, Q1 2024 → Q2 2024: 29,011 shares bought and 27,585 shares sold, net +1,426 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 13 holders
| 22NW, LP | 12.50% | No change | 5,366,290 | $14.6M |
| LVW Advisors, LLC | 0.26% | No change | 642,039 | $1.8M |
| Nantahala Capital Management, LLC | 0.14% | No change | 511,073 | $1.4M |
| Morgan Stanley | 0.00% | No change | 399,219 | $1.1M |
| Ikarian Capital, LLC | 0.13% | No change | 157,862 | $431K |
| Vanguard Group Inc. | 0.00% | Add +0.3% | 153,873 | $420K |
| Geode Capital Management, LLC | 0.00% | Add +125.3% | 51,308 | $140K |
| Boothbay Fund Management, LLC | 0.00% | No change | 18,978 | $52K |
| BlackRock Inc. | 0.00% | Reduce -7.1% | 3,761 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -35.8% | 3,300 | $9K |
| Bank of America Corp. | 0.00% | New | 65 | $177 |
| JPMorgan Chase & Co. | 0.00% | Add +11.1% | 10 | $27 |
| Royal Bank of Canada | 0.00% | Add +34.2% | 51 | $0 |
"% of holder's portfolio" is ANEB's weight in each manager's 13F, not the share of Anebulo Pharmaceuticals Inc. the manager owns.